The ratings of 5 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) slips from a D to a F this week. Teva Pharmaceutical Industries Limited Sponsored ADR is engaged in the provision of pharmaceutical services. The company also gets F’s in earnings growth. For more information, get Portfolio Grader’s complete analysis of TEVA stock.

Novo Nordisk A/S Sponsored ADR Class B (NVO) experiences a ratings drop this week, going from last week’s D to a F. Novo Nordisk A/S Sponsored ADR Class B develops, produces, and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of NVO stock.

This is a rough week for Intra-Cellular Therapies, Inc. (ITCI). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.

Slipping from a D to a F rating, Oculus Innovative Sciences, Inc. (OCLS) takes a hit this week. Oculus Innovative Sciences, Inc. develops and manufactures products to prevent and eliminate infections in chronic and acute wounds. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCLS stock.

Parnell Pharmaceuticals Holdings Ltd. (PARN) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of PARN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.